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Letter to the Editor
We read with interest the article by Ge et al. about a 37 years old
female with MELAS syndrome due to the m.3243A>G variant, man-
ifesting with short stature, hearing impairment, psychiatric disease
(agitation, acoustic hallucinations), hypothyroidism, apraxia, alexia,
epilepsy, migraine, arterial hypotension, lactic acidosis, and a stroke-
like episode (SLE) [1]. We have the following comments and concerns.
We should be informed which of the clinical abnormalities were
transient and attributable to the SLE and which remained part of the
long-term phenotype. It is conceivable that manifestations of the SLE
included seizures, the psychiatric abnormalities, apraxia, and alexia.
Additional features, which may be attributable to a SLE include hemi-
anopia, muscle weakness, aphasia, cognitive impairment, and psychosis
[2]. Which of these additional features were present in the presented
patient? We would also like to know if SLE manifestations completely
resolved and after which time the status quo ante was reached. Occa-
sionally, different SLEs overlap or follow consecutively each other [3].
It is reported that the SLE showed up on MRI as hyperintensity on
DWI and as hypointensity on ADC, thus suggesting a cytotoxic edema.
Cytotoxic edema is characteristic for ischemic stroke. Thus, we should
be informed by which means an ischemic stroke was excluded in the
presented case. Which was the cardiovascular risk profile of this pa-
tient? MELAS may be also associated with cardiac disease, including
systolic dysfunction and atrial fibrillation, diabetes, and hyperlipidemia
[4,5]. Did the patient present with atrial fibrillation, systolic dysfunc-
tion, noncompaction, diabetes, nicotine smoking, or hyperlipidaemia?
Were carotid ultrasound or angiography of the extra-cerebral arteries
normal?
Cerebro-spinal fluid (CSF) investigations were normal but it is not
mentioned if CSF lactate was determined [1]. According to the MR-
spectroscopy there was lactate elevation in the CSF [1]. Was CSF lactic
acidosis confirmed by direct determination of the lactate in the CSF?
Did the patient receive L-arginine orally or intravenously and which
dosage was applied during the acute respectively chronic stage of the
SLE? Particularly during the acute stage of the SLE intravenous L-ar-
ginine should be applied, unless there are any contraindications against
administering this agent.
Obviously, the patient received phenobarbital as an antiepileptic
drug without detailing the dosage and the duration of the application
[1]. From phenobarbital it is well known that it is mitochondrion-toxic
[6]. Did the phenotype deteriorate after administration of pheno-
barbital? Were also other antiepileptic drugs applied?
We do not agree with the statement that thyroid dysfunction is rare
in MELAS/MIDs. Thyroid dysfunction is one of the dominant clinical
manifestations of MELAS [7] and frequently not attributed the under-
lying metabolic disease. However, endocrine disease in general is a
prominent phenotypic feature of MELAS and mitochondrial disorders in
general, why presence of thyroid dysfunction should always raise the
suspicion of an underlying mitochondrial defect.
mtDNA mutations are usually present in the heteroplasmic form in
mitochondrial disorders. Which were the heteroplasmy rates in blood
and parenchymatous organs, such as liver, kidneys, or the myocardium.
Was there a difference between the heteroplasmy rates of the saliva,
fibroblasts, muscle, blood lymphocytes, or the urothelial cells?
mtDNA mutations are maternally transmitted in two thirds of the
cases [8]. We should be informed if the patient's family history was
positive for a mitochondrial defect in first-degree relatives, and if the
mutation was also found in other clinically or subclinically affected
members of the family?
Overall, this interesting case could be more meaningful if the family
history would have been provided, if genetic studies would have been
extended to first-degree family members, if heteroplasmy rates of the
m.3243A>G variant would have been provided in various tissues, if
the multisystem natures of MELAS would have been addressed, and if
organs/tissues not obviously affected, would have been investigated
prospectively.
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